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Myostatin as a regulator of fiber size 
Michal Solecki 
Myostatin is an important negative regulator of muscle mass. Disruption of the myostatin gene 
leads to dramatic increases of skeletal muscle mass. Skeletal muscle is highly plastic and adapts 
in response to changes in workload, activity and pathological conditions. In this thesis, I set out 
to investigate the underlying mechanisms involved in growth in the absence of myostatin. We 
used the myostatin knockout model in combination with synergist ablation or denervation to 
study growth and atrophy. 
During growth induced by functional overload, skeletal muscles increase their mass, midbelly 
and fiber cross-sectional area (CSA), and protein synthesis. The rapid growth also induces the 
activation and proliferation of satellite cells. In skeletal muscle, functional overload in myostatin 
knockout mice led to reduced growth in muscle mass and fiber size and a blunted switch of 
muscle fibers metabolic profile to a slower phenotype compared to their wildtype counterpart. 
Additionally, the distal portion of the plantaris was a region of major remodeling in both groups. 
Denervation through sciatic nerve section is an effective method to induce muscle atrophy. 
Following denervation, a rapid loss in muscle mass and fiber size occurs. Absence of myostatin 
did not prevent muscle mass and CSA loss in response to denervation. Moreover, no changes in 
the expression of MyHC isoforms were found. 
In conclusion, myostatin is not the only regulator skeletal muscle mass. In its absence, 
alternative strategies are employed to reach a different outcome of growth and no protection 
from muscle atrophy was observed suggesting other mechanisms at play. 
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Chapter 1: Introduction 
Myostatin 
The central dogma as enunciated by Crick tells us that all proteins in living cells 
come from DNA[1]. The function of proteins ranges from serving as building blocks to 
regulators and signals of a tight machinery such as myogenesis. Myostatin is such a 
regulatory protein. It was first discovered during a screen for new members of the 
Transforming Growth Factor 3 (TGF-3) superfamily of genes[2]. That same year, it was 
discovered that a mutation in the myostatin gene was causing a dramatic increase in 
muscle mass of cattle[2-4]. Natural mutations in the myostatin gene leading to a 
hypermuscular phenotype have occurred in cattle, sheep and even humans[4-7]. 
Muscles with the mutation have larger myofibers (hypertrophy) and a greater number 
of those muscle cells (hyperplasia). Moreover, animals with a non-functioning or absent 
myostatin gene display a lower fat mass[8, 9]. Gene targeting experiments in mice, 
where the myostatin gene was removed, have led to a similar phenotype[2]. Due to the 
therapeutic potentials, extensive research has focused on myostatin's applications[10-
14]. Thanks to its effects on skeletal muscle, the removal or inhibition of myostatin is an 
effective method to treat many pathological states[10, 12, 13]. It has also been shown 
to be effective in functional improvements in muscular dystrophy[10, 12]. Aged 
myostatin-null mice display no fiber type changes related to ageing[13]. Additionally, 
regeneration is accelerated in the myostatin-null mice when compared to the age-
matched wildtype mice. 
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Member of the TGF-p Family 
Myostatin is similar in structure and functions the same as the rest of the TGF-P 
family (Fig. 2). The family is divided into three subfamilies: TGF-p, bone morphogenic 
protein, and activin[15]. When myostatin is synthesized, it first appears as a precursor 
protein that contains the active ligand and the propeptide[16]. Once processed, mature 
myostatin is secreted[2,16], suggesting a systemic role. The propeptide can bind to the 
mature myostatin producing an inactive complex that is prevented from binding to 
response sites[16,17]. The signaling functions through three main components: the 
ligand, the receptors, and the intracellular mediators (Smads)[18] (Fig. 1). The signaling 
begins with the ligand binding to its type II receptor (Fig. 1-1). The type II receptor binds 
wi th its corresponding type I receptor (Fig. 1-2&3) and will activate the complex (Figl-4) 
and, in turn, activate the Smad protein (Fig. 1-5). The Smad proteins can form a complex 
wi th a common Smad termed Smad4 (Fig. 1-6). The Smad complex can enter the nucleus 
(Fig. 1-7) to regulate transcription in a cell-type-specific manner (Fig. 1-8&9)[19]. 
Another set of Smads, inhibitor Smads (Smad6 and Smad7) serve to stop TGF-P signaling 
by an auto-inhibitory l o o p [ l l ] . In the case of myostatin, the active myostatin ligand 
binds preferentially to Activin Receptor llb[20]. It can also bind, with lower affinity, 
Activin Receptor lla[20]. The type II receptor will bind to either ALK-5 or ALK-4 
receptors[20]. The binding of myostatin to either type II receptors will activate Smad2 
and Smad3, then, will form a complex with Smad4. To counteract the myostatin 
signaling, Smad7 is involved in a negative feedback loop where Smad7 expression is 
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induced by myostatin and the overexpression of Smad7 leads to inhibition of 
myostatin[21]. 
Myostatin's role in myogenesis 
Disruption of myostatin signaling induces hyperplasia. The addition of new muscle cells 
occurs through a process called myogenesis. Myogenesis is involved during 
development and regeneration following a trauma. It is a process that can be separated 
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Figure 1 TGF-0 signaling pathway 
(1) The ligand binds to the type II receptor. (2) The type II receptor associates with the type I receptor. (3) The two 
receptors form a complex. (4) The complex is activated. (5) The Smad protein is activated. (6) The Smad protein forms 
a complex with Smad4. (7) The Smad complex enters the nucleus. (8) The Smad complex with a DNA-bindirig partner 
binds DNA. (9) The complex initiates the transcription of specific genes. Image taken from [19]. 
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cells. This process is under the regulation of a family of proteins called Muscle 
Regulatory Factors (MRFs) (Fig. 2)[22-25]. The MRF family includes Myf5, MyoD, 
myogenin and MRF4[22]. Each of these factors has overlapping but also distinct 
functions in myogenesis. Indeed, it has been reported that Myf5 enhances myoblast 
proliferation, whereas MyoD induces differentiation by cell cycle withdrawal[26]. 
Myogenin is required for the differentiation of myoblasts[27] and MRF4 is thought to be 
important in the maturation of myotubes[28, 29]. 
Satellite cells are adult skeletal muscle stem cells that are involved in myogenesis 
following a trauma[30]. The satellite cells reside beneath the basal lamina juxtaposed to 
muscle fibers[30]. Under normal conditions, satellite cells remain quiescent but can be 
activated due to damage caused by mechanical stress[31-34], chemical injection[34] or 
extreme cold[35]. With a modest stimulus, satellite cells divide, differentiate and can 
fuse with pre-existing myofibers[30, 34]. In more extreme circumstances, the myoblasts 
that form after satellite cell division can fuse together and give rise to a new fiber within 
the basal lamina[32, 33]. 
The quiescence of the satellite cells is controlled by another regulatory protein 
called paired-box 7 (pax7)[36, 37]. The Pax genes have important roles in tissue 
specification and organogenesis such as the central nervous system (Pax2, 3, 5-8), 
kidneys (Pax2 and 8) and skeleton (Paxl and 9)[38]. The different functions of the Pax 
genes include the maintenance of a multipotent state, direction into a differentiation 
program, cell migration, proliferation, and survival[38]. In skeletal muscles, Pax3 and 
Pax7 appear to be implicated in these functions in satellite cells. Pax3 is especially 
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important in the embryo for the migration of muscle progenitors from the somite to 
more distant sites of myogenesis. Pax3 is also necessary for the activation of Myf5 
following this migration to activate the myogenic program[39]. Subsequent myogenesis 
depends on Pax3 and Pax7. These new cells provide a source of myogenic progenitors 
for all subsequent muscle growth[38]. During the early postnatal period, approximately 
30-35% of nuclei come from satellite cells [40, 41]. Over time, this proportion falls to 
only l-4%[42].Later on, Pax7 is especially important for satellite cell survival and 
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Figure 2 Myogenesis and MRFs 
Pax7 maintains satellite cell quiescence, but upon activation, the primary MRFs, Myf5 and MyoD, are required for 
myogenic determination, whereas, the secondary MRFs, myogenin and MRF4, are required for differentiation. Image 
adapted from [43,44]. 
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To understand the mechanism by which myostatin regulates muscle mass, gain 
and loss of function analysis was done in cell culture. Myostatin addition to the cell 
culture inhibits myoblast proliferation and differentiation[45-47]. This inhibition is also 
dose-dependent[45]. Myostatin prevents the progression of myoblasts through the cell 
cycle[45]. Smad3 is known to interfere with MyoD[48], and therefore, the reduction in 
activity of MyoD could interrupt the cycle[47]. 
Myostatin and activation of satellite cells 
Myostatin is present in satellite cells and myoblasts[49]. Not surprisingly, 
increased activation of satellite cells occurs in the absence of myostatin[49]. It is also 
important to note that, in vitro, myoblasts from Mstn-/- mice stopped proliferating and 
differentiated into myoblasts much later than myoblasts taken from wildtype (Mstn+/+) 
mice. In the Mstn-/- myoblasts, myoD is expressed for a longer period of t ime and the 
induction of myogenin is delayed when compared to the wildtype {Mstn+/+) 
counterpart[49]. Additionally, myostatin signals through Pax7 to regulate satellite cell 
renewal[50]. Myostatin addition severely downregulates Pax7 expression and absence 
of myostatin causes an upregulation in Pax7[50]. In vitro, cells from myostatin-null mice 
display higher levels of Pax7[50]. During differentiation, lack of myostatin results in an 
increased pax7 expression and those elevated levels are maintained considerably 
longer[50]. More recently, a controversial study found that the loss of myostatin does 
not lead to increased satellite cell activation and the increased muscle mass is mostly a 
result of hypertrophy[51]. As mentioned previously, myostatin's inhibitory action on 
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satellite cells is dose-dependent; however, the concentration used in the latest study 
was below a concentration where no effect was previously observed[45, 47]. 
Myostatin and growth pathways 
One of the best known growth-promoting factor is the insulin-like growth factor, IGF-I. 
IGF-I is synthesized in the liver under growth hormone (GH) control[52]. The induction 
of hypertrophy by IGF-1 is dependent on a pathway initiated by phosphatidylinositol-3-
kinase (PI3K) which regulates Akt. Targeted activation of Akt also leads to muscle 
growth[53, 54]. Surprisingly, Akt activation does necessarily occur through the IGF 
receptor following increased mechanical loading on skeletal muscle[55]. 
Moreover, IGF-I is thought to induce the activation of satellite cells[56]. Most of 
the data is restricted to cell culture, however, muscle hypertrophy by delivery of IGF-I is 
blocked by irradiating the muscle[57]. Irradiation is thought to prevent satellite cell 
activation, however, little is known about the non-specific effects on other cell types[58, 
59]. A recent study has shown that Akt activation does not lead to satellite cell 
activation[60]. The authors did not, however, label satellite cells to determine the 
amount of growth attributable to satellite cell activation. Myostatin has also been found 
to interact with the IGF pathway (Fig. 3). In vitro, overexpression of myostatin 
attenuates myotube growth and reduced Akt phosphorylation[61, 62], whereas the 
absence of myostatin is sufficient to induce growth[61]. Inhibition of Akt 
phosphorylation also blocks myostube hypertrophy even in the absence of 
myostatin[61]. 
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Protein synthesis Differentiation Protein degradation 
Increased Skeletal muscle size 
Figure 3 Myostatin and IGF signaling interactions 
Many interactions are known to exist between the myostatin and IGF pathways. Redundancies are found at different 
levels and act the pathways in concert to balance the size of skeletal muscle. Image modified from [63], 
Myostatin and atrophy pathways 
Atrophy is defined as a decrease in cell size mainly caused by a loss of organelles, 
cytoplasm and proteins[64]. In the case of skeletal muscle, atrophy occurs when the rate 
of protein degradation exceeds the rate of protein synthesis[65]. Gene expression 
comparison in different models of atrophy shows a subset of genes commonly up- and 
downregulated in muscle. These genes that are common to all atrophy models are 
called atrophy-related genes or atrogenes[66], suggesting a process controlled by 
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specific signaling pathways. The two most induced genes in skeletal muscle specifically 
are responsible for protein degradation: atrogin-1 and MuRFl[67, 68]. 
Atrogin-1 and MuRFl are known to induce protein degradation by using the ubiquitin-
proteasome system[67]. In this system, proteins are tagged and degraded by a 
proteasome[69, 70]. The specificity of the tagging is due to the ubiquitin ligases which 
contain a specific target-recognition subunit[69]. Atrogin-1 and MuRFl are ubiquitin 
ligases. Some of the identified targets of atrogin-1 are MyoD and myogenin[71, 72]. 
Importantly, recent findings suggest MuRFl is involved in the degradation of 
MyHCs[73]. The knockout of either MuRFl or atrogin-1 makes mice partially resistant to 
atrophy. 
Under atrophic conditions, treatment with IGF-I results in reduced activation of MuRFl 
and atrogin-l[74, 75]. Akt can stimulate skeletal muscle hypertrophy but also inhibits 
atrophy. The mechanism by which Akt regulates atrogin-1 and MuRF-1 involves the 
FoxO family of transcriptions factors [74, 75]. Phosphorylation of FoxO proteins 
promotes the export of FoxOs from the nucleus to the cytoplasm. Upon 
dephosphorylation, FoxO proteins translocate to the nucleus[76]. Accordingly, mice 
overexpressing FoxOl show a markedly reduced muscle mass, further supporting the 
role of FoxO In atrophy[77]. 
In many different models of atrophy such as disuse, denervation, disease and 
sarcopenia, myostatin is increased[78-81]. A link between myostatin's function and 
atrophy was found through FoxOl. FoxOl can bind to myostatin's promoter region and 
increase the expression of myostatin[82]. This effect can be potentiated in the presence 
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of Smad proteins[82]. Furthermore, myostatin treatment induces cachexia by inhibiting 
Akt phosphorylation and thereby increasing levels of active Fox01[83]. This suggests 
that myostatin is involved a feed forward mechanism where myostatin increases FoxO's 
activation, which in turn, increases myostatin's expression. 
Metabolic changes in Mstn-/- mice 
Changes in the expression of different isoforms of the major contractile protein of 
skeletal muscles, myosin, have also been observed. Myostatin-null mice have a greater 
proportion of fast glycolytic fibers in all skeletal muscles studied[84-86]. Interestingly, in 
animals expressing normal levels of functioning myostatin, fast muscles express more 
myostatin and this expression is highly correlated with the proportion of fibers 
displaying MyHC llb[81]. MyoD, a muscle regulatory factor, preferentially expresses 
MyHC Mb. In turn, myostatin-null mice express higher levels of MyoD[86]. It has been 
indeed shown that MyoD is one of myostatin's targets[47, 86]. To further support 
myostatin's role in the switch towards a faster glycolytic phenotype, functional 
assessment of ATPase and succinate dehydrogenase (SDH) activity confirms a shift 
towards a faster and more glycolytic phenotype in myostatin-null mice[85]. 
Furthermore, the number of mitochondria is reduced[85]. 
Factors affecting muscle growth 
Functional overload involves surgical removal of synergistic muscles causing a 
rapid growth response that leads to increased muscle mass, greater muscle midbelly 
and fiber cross-sectional area and protein synthesis[87-91]. In two to four weeks of 
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overload, the plantaris mass almost doubles[91]. These changes are also marked by a 
change in myosin heavy chain expression that follows a fast-to-slow transition[89, 90]. 
The time-course of changes following the compensatory response to removal of 
synergistic muscles occurs in two distinct phases: an immediate short-term 
inflammatory reaction and a slower long term adaptation to the elevated demands on 
the muscle[92]. 
The initial phase involves increased water content and invasion of the muscle by 
inflammatory cells[92]. The invasion is very rapid since two hours is sufficient to detect 
significant changes in the population of neutrophils[93]. The peak response occurs 
within the first 24 hours and is maintained up to five days post-surgery, after which the 
response declines[92]. By two weeks after the surgery, the levels of inflammation are 
back to normal. At the same t ime, markers of myogenesis become significantly higher 
after just 12 hours of overload[94]. 
Further on, the anabolic effects of IGF-I are well known. IGF-I can induce 
hypertrophy both in vitro and in v/Vo[95, 96]. Insulin-like growth factor I (IGF-I) is also 
upregulated 3 days following overload[97, 98] and its downstream target Akt becomes 
phosphorylated[54]. This increase in the growth factors is growth-hormone 
independent[98]. However, IGF-I has also been found to be dispensable to induce 
hypertrophy following functional overload[55]. The rapid initial growth has also been 
attributed in part to the proliferation of satellite cells[59]. Following, hypertrophy, the 
ratio of nuclei to cytoplasmic volume is maintained and it would therefore require new 
cells to donate their nuclei[57, 99]. Since muscle is formed of post-mitotic cells, 
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hypertrophy is dependent on activation of satellite cells and their fusion into existing 
myofibers[100]. 
Following the acute response to overload, slower adaptations in the 
morphological and biochemical structure will occur. The changes in MyHC expression 
are extensively described with significant differences after only two weeks[89, 91,101]. 
During that time frame, the expression of MyHC lla is already increased and remains 
high. After four weeks, the proportion of fibers expressing MyHC I increases as well. The 
reduction in MyHC lib is apparent after six weeks of overload. Changes in activity of 
different enzymes are coordinated with the expression of distinct MyHC isoforms 
following functional overload. The oxidative enzyme SDH activity increases, whereas the 
glycolytic glycerol-3-phosphate dehydrogenase (GPDH) activity declines[89]. Recently, a 
few studies have tried to determine the capacity of the genetically altered mice to 
perform exercise and to adapt to the functional demands[102-104]. Mstn-/- mice have a 
reduced exercise capacity; however, the amount of daily exercise performed varies 
among the studies[103,104]. More importantly, the muscles of Mstn-/- mice maintain 
their plasticity to meet the functional demands[102, 103]. 
Factors involved in muscle atrophy 
Denervation through sciatic nerve section is an effective method to induce atrophy. 
Similar to all disuse models, 2 weeks of denervation in rodents causes a reduction in 
muscle mass between 30-50% wi th a concordant change in individual fiber size[66, 79, 
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105]. Just as in overload, changes in MyHC expression also occur; however, 
discrepancies exist among the studies as to the direction of the switch[105-108]. 
Denervation atrophy has an initial rapid, then slow phase[66, 79]. During the first two 
weeks, up to 50% of the muscle mass is lost. Longer studies up to eight weeks show no 
additional loss[66, 79]. 
Many genes are differentially expressed during the initial phase. MuRFl and MAFbx are 
among the mRNA most drastically induced by denervation[66, 109, 110]. These 
atrogenes start rising after one day of denervation, reaching their peak at three 
days[66]. The expression of those genes is dependent on the FoxO family of 
transcription factors, FoxOl and Fox03a[74,109, 111]. Fox03a directly binds to the 
MAFbx promoter region and induces its transcription; whereas FoxOl, synergistically 
with the glucocorticoid receptor, induces the expression of MuRFl. Although, the levels 
of MuRFl and MAFbx return to basal levels after 14 days, FoxOl can remain elevated up 
to 28 days following surgery[66]. Besides protein degradation, apoptosis also 
contributes to muscle mass loss[112]; however, the earliest time point where apoptosis 
can be detected is two months[113]. 
Changes in the expression of the different isoforms of MyHCs are well described in 
rats[106, 114]. The direction of the change depends on the predominant fiber type of 
the muscle prior to denervation[106, 115]. Fast muscles develop a tendency towards a 
slower phenotype and slow muscle show a shift towards a fast phenotype. The effect of 
denervation on mice appears to differ f rom rats since mice do not lose MyHC l[105]. 
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However, mice still show a reduced oxidative capacity, typical of denervation-induced 
atrophy. 
In wildtype animals, myostatin expression levels rise very rapidly and peak after three 
days of denervation[79]. The protein levels peak at seven days and remain elevated up 
to 28 days[79]. A similar trend can be seen in myostatin's downstream target, the 
phosphorylated Smad2[79]. As mentioned previously, myostatin's expression is muscle 
specific and its expression correlates with the percentage of MyHC Mb isoforms 
expression[81]. In fact, no myostatin is found in the soleus muscle[81]. It is not 
upregulated in soleus either when atrophy is induced by hindlimb unloading[81] 
suggesting an alternative pathway. Different models of atrophy consistently lead to an 
upregulation of myostatin[78, 81 , 116-120]. 
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Introduction to manuscripts 
The following chapters are manuscript to elucidate myostatin's role in regulating muscle 
fiber size. We used the myostatin knockout model to assess whether absence of 
myostatin 1) enhances muscle growth when forced to hypertrophy and 2) protects 
skeletal muscles from atrophy. 
Myostatin is involved in satellite cell activation and in growth pathways. No study up to 
date has focused on the capacity of myostatin-null mice to activate satellite cells 
following synergist ablation. Myostatin is downregulated following functional 
overload[98]; however, the capacity of these muscles to undergo the changes that occur 
in the absence of myostatin has not been determined. I hypothesize that functional 
overload will induce a potentiated growth in myostatin null mice. This growth would be 
a result mostly due to greater hyperplasia. 
As mentioned previously, myostatin is upregulated in different models of skeletal 
muscle atrophy. Treatments targeting the myostatin pathway can also partially prevent 
atrophy. However, the effects of constituent knockout of myostatin on denervation 
have not been studied so far. I hypothesize that muscles from Mstn-/- mice will be 
spared from atrophy normally observed following denervation. 
15 
Chapter 2: Myostatin attenuates hyperplasia and is 
important for muscle remodeling during compensatory 
growth 
Manuscript in preliminary phase of preparation 
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Abstract 
Myostatin is a negative muscle mass regulator part of the TGF-R family of growth 
factors. The increase in muscle mass is a result of hypertrophy and hyperplasia. To 
investigate the role for myostatin (Mstn) in muscle fiber remodeling, we compared the 
effects of functional muscle overload of the plantaris in Mstn Knockout (Mstn -/-) and 
wildtype {Mstn+/+) mice. The muscle midbelly area of non-overloaded (OV) Mstn-/-
mice was double that of Mstn+/+ counterparts due to a higher number of muscle fibers 
and fibers displaying greater cross sectional size. Six weeks of functional overload led to 
a blunted growth marked by significant differences in the increase in mean midbelly 
area (Mstn+/+: 90%; Mstn-/-: 23%; p<0.05). The blunted growth was concomitant with 
increases in individual fiber sizes (Mstn+/+: 35%; Mstn-/-: 8%; p<0.05). Additionally, 
muscles from Mstn-/- mice maintain the plasticity to adapt to functional demands as 
marked by changes in the expression of the different isoforms of MyHC, however, that 
response was also blunted. Following the surgery, the distal portion of the plantaris 
muscle was a region of major remodeling in both groups. Compared to their wildtype 
{Mstn+/+) counterparts, Mstn-/- mice displayed more damage marked by EBD and more 
regeneration marked by 5-bromo-2'-deoxyuridine (BrdU) and myogenin. This 
differential growth pattern may be of importance when considering Myostatin-related 




Myostatin is a negative muscle mass regulator part of the TGF-IS family of growth 
factors[121, 122]. Natural mutations in the myostatin gene leading to a hypermuscular 
phenotype have occurred in cattle, sheep and even humans[4-7]. Mice lacking 
myostatin display a doubling in muscle mass as a result of hyperplasia and 
hypertrophy[122]. By binding to its receptor, activin lib receptor[123], myostatin inhibits 
the proliferation and differentiation of muscle fibers. This effect was also observed in 
vitro using c2cl2 cells[124, 125]. Following the binding of myostatin to its receptor, a 
signaling cascade involving Smad proteins[126, 127] begins and results in the inhibition 
of the growth PKB/AKT pathway and activation of the atrophy pathway through the 
forkhead box O (FOXO) transcription factor and Muscle Ring Finger 1 (MuRFl) / Muscle 
Atrophy F-box (MAFbx) (also known as atrogin-l)[128-131]. 
Plantaris muscle functional overload is a well established model to study muscle 
growth in rodents[88, 132]. It is achieved by removing synergist soleus and 
gastrocnemius muscles. The changes following the surgery occur in two distinct phases. 
The long term changes are well documented and are characterized by increased muscle 
mass, greater midbelly area, an increase in midbelly fiber size as well as protein 
synthesis[133, 134]. The muscle fibers also undergo a transition from fast, glycolytic, to 
slower, more oxidative energy efficient phenotypes. In rodent fast muscle, the myosin 
heavy chain enzyme component of myosin follows a conversion pattern in response to 
overload from the fastest to the slowest isoform in the order: MyHC lib -> llx -> Ha -> 
l/slow[135-137]. In control plantaris muscles, cells expressing the various MyHCs display 
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distinct metabolic profiles[89]. Muscle fibers expressing MyHC Ma have a greater mean 
SDH activity than all other isoforms in the order: Ha -> I -> llx -> lib. As for GPDH 
activity, fibers expressing MyHC Mb and llx have the greatest mean activity followed by 
fibers expressing MyHC Ma and I. Changes in activity of metabolic enzymes are also 
coordinated with the expression of distinct MyHC isoforms following functional 
overload. The oxidative enzyme SDH activity increases, whereas the GPDH activity 
declines[89]. Most recently, studies have demonstrated that Mstn-/- muscles 
maintained the plasticity to increase their oxidative capacity following exercise[102, 
103]. 
The initial phase following the surgical ablation involves increased water content 
and invasion of the muscle by inflammatory cells[92]. The peak response occurs with 
24hrs and is maintained up to five days post surgery. By two weeks, the levels of 
inflammation are back to normal[92]. 
The literature on muscle damage following functional overload is limited due to 
the confounding inflammation, however, unloading/reloading, stretch and eccentric 
contractions are known to cause muscle damage[31, 138, 139]. Most importantly, the 
location of the injury and regeneration remains consistently in the distal portion of the 
plantaris muscle[138]. Interestingly, proliferating cells were found mostly in the distal 
regions of plantaris muscle in overload rats[140]. Muscle regeneration after injury has 
similarities to muscle development during embryogenesis and seems to follow the same 
procedure[141]. Muscle satellite cells, normally located within the basal lamina of the 
muscle, become activated, proliferate and differentiate to become mature muscle 
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fibers. Following differentiation, satellite cells can incorporate their nuclei into pre-
existing fibers to repair damaged fibers[142,143]. Interestingly, satellite cells were 
found to be more concentrated at the ends of growing muscle fibers[144]. In their 
quiescent state, satellite cells are found to express Pax7 and/or Myf5[145-148]. The 
population of satellite cells in muscles remains fairly constant throughout adult life 
which requires the satellite cells to possess a self-renewal capacity, a phenomenon still 
poorly understood[149, 150]. One of the stimuli known to activate satellite cells is 
functional overload[151]. 
To better understand Myostatin role in growth, we subjected wildtype (Mstn+/+) 
and Mstn Knock-out mice (Mstn-/-) to functional overload for different periods of t ime. 
We hypothesized the plantaris of OV Mstn -/- mice would have a potentiated growth 
response implicating muscle satellite cells compared to Mstn+/+ OV counterparts. 
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Materials and methods 
Animal care and protocols 
All animal care and experimental procedures were performed in accordance with 
the guidelines established by the Canadian Council of Animal Care. These procedures 
were approved by the University Animal Research Ethics Committee (UAREC) of 
Concordia University. Mstn-/- mice were kindly donated by Dr. S.-J. Lee. (Johns Hopkins 
University School of Medicine, Baltimore, MD) 
Animal surgeries 
All surgical procedures were performed under aseptic conditions on animals 
anesthetized by intramuscular injection (1.2 pl/g) of 100 mg/ml ketamine hydrochloride 
and 10 mg/ml xylazine in a volume ratio of 1.6:1. For OV experiments, compensatory 
hypertrophy of the plantaris was induced in each in limb in Mstn+/+ and Mstn -/- mice 
by surgically ablating the soleus and a major portion of the gastrocnemius muscle. The 
mice were overloaded for periods of 24 hours, 3 days, 7 days, 14 days or 42 days. 
Following the surgeries, the mice were given children's ibuprofen diluted in water for 
the first 3 days. No ibuprofen was added for the rest of the duration of the functional 
overload period. After a period of convalescence (3-7 days), the OV mice were exercised 
daily for 60 minutes by placing them in an exercise ball (12 cm diameter). Plantaris, 
Tibialis anterior, Extensor digitorum longus muscles from control or overloaded mice 
were excised and either frozen directly in liquid nitrogen or embedded in OCT (Tissue-
Tek, Torrance, CA) and frozen in melting isopentane before being put in liquid nitrogen. 
Tissues were stored at -86°C until processed. 
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Cell nuclei labeling 
During cell division, DNA is replicated to generate 2 identical cells. 5-bromo-2'-
deoxyuridine (BrdU), a synthetic nucleoside, can substitute for thymidine during DNA 
replication [152]. The inserted BrdU can then be labeled with a specific antibody, thus 
indicating the nuclei that have undergone DNA replication. The proliferation in the 3-day 
overloaded plantaris muscle was assessed by the uptake of BrdU [91]. Briefly, 50mg/kg 
of body weight was injected daily intraperitoneal^. The first injection was administered 
following the overload surgery; the others were done at 24 hour intervals and the last, 2 
hours prior to extraction. 
Immunohistochemistry 
Antibodies used were: MyHC I: A4.840, (1:25, Developmental study hybridoma bank 
(DSHB), University of Iowa, Iowa city, IA); MyHC lla: SC71 (1:12.5; DSHB); MyHC llx: 6H1 
(undiluted; DSHB); MyHC lib: BF-F3 (1:25; DSHB); MyHC emb I: F1.652 (1:10; DSHB); MyHC emb 
II: 47A (1:10; DSHB); anti-mouse HRP : IgG A8924 (Sigma-Aldrich) or IgM A8786 (Sigma-Aldrich). 
To determine the MyHC isoform expressed by each fiber, cryosections (10 pm) were cut 
from the same anatomical location in each muscle midbelly and recovered onto 
Superfrost Plus microscope slides (Fisher Scientific). First, the sections were blocked in 
5% goat serum in a carrier solution consisting of 0.5% bovine serum albumin (BSA) in 25 
mM phosphate buffer solution (PBS) (pH = 7.4) for 30 minutes. The sections were then 
probed overnight at 4°C in carrier solution with one of the following primary antibodies 
raised against the different MyHC types (I, lla, llx, Mb, Embryonic). After three 10-min 
PBS rinses, sections were then probed at room temperature with either horseradish 
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peroxidase-conjugated anti-mouse IgG (MyHCtype lla, 1:25; Embryonic, 1:50) or IgM 
(MyHC type 1, llx, lib; 1:25) (Sigma-Aldrich). The sections were rinsed three times with 
PBS for 10 minutes. The bound antibody complexes were then visualized using 
diaminobenzidinetetrahydrochloride (DAB) as per the manufacturer's instructions (Thermo 
Fisher Scientific, Rockford, IL). DAB makes the bound peroxidase-conjugated antibodies 
turn brown and can be visualized with a light microscope. 
Three to five distinct regions were selected randomly from the midbelly of each 
plantaris muscle. All fibers in those regions were identified across each serial tissue 
section with the aid of a Retiga SRV camera (Qlmaging, Surrey, BC, Canada) mounted on 
an Olympus BX-60 (Olympus, Center Valley, PA) microscope. Each area of interest 
comprised approximately 75 fibers. The images were analyzed using ImagePro Plus 
version 6.2 software (Media Cybernetics, Bethesda, MD). Fibers were classified 
according to their staining profile with the distinct antibodies. For consistency, cell size 
was measured on a single non-stained muscle section fixed with 1% paraformaldehyde 
for 20 minutes in PBS followed by 3 washes in PBS for 5 minutes each. 
For central nucleation, muscles cryosections (10 u.m) were obtained and 
recovered on Superfrost® Plus Slides. The slides were processed for hematoxylin and 
eosin staining, dehydrated and mounted. Images were captured covering the whole 
belly and all muscle fibers were classified according to the number of centrally located 
nuclei. Results were normalized to the belly area. 
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SDH and GPDH activity 
SDH and GPDH activity was measured as described previously[136]. All images were 
captured with the aid of a Retiga SRV camera mounted on an Olympus BX-60 
microscope. OD analysis was completed using ImagePro Plus version 6.2. For SDH, serial 
sections (14u.m) of muscle were cut from the plantaris muscle midbelly and were 
adhered to slides. The slides were placed under a microscope. The tissue was first 
incubated in the dark at 23°C in a substrate-free blank solution consisting of 1 mM 
sodium azide, 1 mM l-methoxyphenazine methosulfate (MPMS), 1.5 mM NBT, and 5 
mM EDTA in 100 mM sodium phosphate buffer (pH 7.6). The reaction was allowed to 
proceed for 10 min to allow for endogenous staining to plateau. The blank was then 
replaced with a substrate solution consisting of the above reagents plus 48 mM succinic 
acid. Images were captured every 2 min for 10 min. During this t ime, increases in optical 
density (OD) are linear (data not shown). 
For measurement of single fiber GPDH activity, serial sections (14 pm) were cut, 
adhered to slides, and distributed between two coplin jars kept at -20°C. A blank 
solution consisting of 1 mM sodium azide, 1 mM MPMS, 1.2 mM NBT in 100 mM sodium 
phosphate buffer (pH 7.4, 37°C) was added to one jar while a solution of the above 
reagents plus 9.3 mM a-glycerophosphate was introduced into the other for the 
substrate reaction. Tissue sections were incubated in the dark for 24 min at 37°C. The 
reactions were then stopped by extensive rinsing with distilled water (5 times plus 3 x 1 
min). Sections were air-dried and mounted with glycerine (Sigma). Images of the blank 
and end-point substrate reactions were captured and processed for OD analysis. 
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The average grayness for all pixels within this traced area was determined across all 
saved sequential images and converted to an OD value. The enzyme specific activities 
were expressed as the change of OD over t ime (OD/min; average r2 > 0.99). The cross-
sectional area of each traced cell was also determined from these images. The total 
enzyme activity within each cellular tissue section was calculated by multiplying the CSA 
of each fiber by its specific enzyme activity. The CSA of each whole midbelly section was 
also determined using this same system for comparison among groups. 
Evans Blue Dye staining 
To visualize muscle fibers that sustained injury following overload, Evans blue dye was 
injected as described previously[93]. Briefly, 24 hours prior to muscle extraction, 
animals were injected intraperitoneal^ with 100 mg/kg body weight of Evans Blue Dye 
(5% w/v of Evans Blue in PBS, pH = 7.4). Evans blue binds to albumin and other serum 
proteins which normally are impermeable to cell membranes. Muscle fibers that 
sustained damage to their membrane will absorb the albumin bound to the dye[153], 
where it can be visualized by fluorescence microscopy at an emission of 515 nm. To 
determine the location of the damage, thick sections (20 urn) were obtained at the 
midbelly and 2 mm distal from the midbelly close to the Achilles tendon. For 
longitudinal sections, the plantaris muscle was oriented to obtain sagittal sections. Once 
recovered on a slide, each muscle section was quickly covered with cold EDTA (4°C, 
0.5M, pH 8.0) for 30 seconds. Following abundant washes (10x30seconds), the slides 
were dried and covered with glycerine. As control for EBD staining, we injected mdx 
mice displaying a similar but less severe phenotype of Duchenne muscular dystrophy. 
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Protein extraction and immunoblotting 
Antibodies used were: Pax7,1:10: PAX7 (DSHB); Myogenin, 1:10: F5D (DSHB); MyoD, 
1:1000: C-20 (Santa Cruz Biotechnology); alpha tubulin, 1:2000: 2125 (Cell Signaling 
Technology); anti-mouse HRP, 1:1000: A8924 (Sigma-Aldrich); anti-rabbit HRP, 1:1000: 7074 
(Cell Signaling Technology). Muscles were homogenized in RIPA buffer [PBS (pH 7.4), 1% 
Igepal, 0,5% Sodium deoxycholate, 0,1% SDS, 10 u.g/ml leupeptin, 10 u.g/ml aprotinin, 1 
mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 10 m M NaF, and 1 mM sodium ortho 
vanadate] using a TissueTearor homogenizer (ColeParmer, Montreal, QC) at low speed 
for 45 seconds. Homogenates were centrifuged at 13 000 x g for 30 min at 4°C to pellet 
cell debris. The supernatant was quantified using the QuickStart Bradford dye reagent 
(Bio-Rad, Mississauga, Ontario, Canada). For protein analysis, 150 u.g protein were 
resolved by SDS-PAG, transferred to a PVDF membrane (Millipore). The protein/antibody 
complex was revealed by chemiluminescence using the Immobilon Western kit 
(Millipore). 
Immunofluorescence 
Antibodies used were: Myogenin, 1:50: G20 (Santa Cruz Biotechnology Inc, santa Cruz, CA); 
BrdU, 1:50, 250563 (Abbiotec, San Diego, CA); anti-goat Alexa488, 1:100, A11055 (Invitrogen, 
Burlington, ON); anti-rabbit Alexa546,1:100, A11010 (Invitrogen). 10 u.m sections of plantaris 
muscles were recovered onto Superfrost Plus microscope slides (Fisher Scientific). The 
tissue sections were then fixed with 2% paraformaldehyde for 20 minutes (Sigma-
Aldrich) and washed 3 times (5 minutes each) with PBS. Sections were blocked and 
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permeabilized with 2% normal goat serum (Sigma-Aldrich) and 0.2% Triton X-100 
(Sigma-Aldrich) for 1 hour. Sections were then incubated overnight at 4°C with the 
antibodies listed previously in PBS containing 1% normal goat serum and 0.05% Triton X-
100. Slides were then washed 3 times with PBS and secondary antibodies as listed 
previously were applied for 1 hour at room temperature in PBS containing 1% normal 
goat serum and 0.05% Triton X-100. Slides were washed 5 minutes 3 times and air-dried. 
Sections were mounted in Vectashield containing 1.43nM DAPI (Vector Laboratories, 
Burlington, ON). Control experiments omitt ing primary antibodies revealed absent or 
very low-level background staining. Images were acquired on an Olympus BX-60 
fluorescent microscope (Olympus) using Image-pro 6.2 software (Olympus). 
Statistical analytsis 
The data was tested for homogeneity of variance, and in the case where homogeneity 
was found, a two-way ANOVA was used. LSD was used as a post hoc test when 
appropriate. When the variance between the groups was not homogenous, the Kruskal-
Wallis test was performed. The statistics were done with computer assistance using 
SPSS Statistics GradPack version 17.0. 
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Results 
Comparison of control phenotypes 
The muscle midbelly area and muscle weight of the control Mstn-/- plantaris muscle was 
significantly greater when compared to the Mstn+/+ mice (Fig. 4A & C) (midbelly area: 
67% and muscle weight: 76%; p<0.05). Even when controlled for the greater body 
weight, the relative muscle weight of the Mstn-/- was still significantly higher (Fig. 4C) 
(55%; p<0.05). This was due to a greater number of muscle fibers (30%) and also larger 
individual cross-sectional areas (29%) (Fig. 4D). Additionally, the proportion of muscle 
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Figure 4 Morphological changes upon overload 
A) Absolute muscle weight over the time-course in MSTN+/+ (open bars) and Mstn-/- (closed bars) mice. B) Plantaris 
absolute muscle weight relative to body weight. C) Mean midbelly area. D) Mean cross-sectional size of individual 
fibers irrespective of the MyHC expressed. Values for all graphs are means + S.E. n=4-7 per treatment group. * 
different (p<0.05) from wildtype (Mstn+/+) counterpart, ¥ different (p<0.05) from non-overloaded control, n different 
from 3-day overloaded muscles, § different (p<0.05)from 2-week overloaded groups. 
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fibers expressing MyHC lla (42%; p<0.05) compared to wildtype (Mstn+/+ mice (Fig. 5). 
fibers expressing MyHC lib was greater in Mstn-/- (42%; p<0.05) and less of the smaller 
Mstn-/- plantaris muscles did not show any fibers expressing MyHC type I. 
Muscle morphological changes 
The results of the statistical analysis related to the changes observed can be found in 
table 2. As expected, 2 and 6 weeks of functional overload resulted in significant 
increases in absolute plantaris muscle mass (Fig. 4A) for both groups with no significant 
differences between the groups (Mstn+/+: 82-105%; Mstn-/-: 25-42%; p<0.05). After 
controlling for the body weights, a tendency for Mstn-/- to grow less in relative muscle 
mass was observed (Fig. 4B). The changes in relative muscle weight corresponded to 
increases in the mean cross-sectional size of all plantaris MyHC-typed fibers (Fig. 4D). 
Table 1 Statistical analysis results of morphological changes 
p-values for the main effects and interactions of each variable. Asterisks denote significance (p<0.05) 




CSA of fibers expressing: 
All fibers combined <0.001* 
MyHC I 0.306 
MyHC lla 0.196 
MyHCIIx 0.371 
MyHC lib 0.497 
Midbel lyArea <0.001* 




















Significant interactions were found in the growth response where the mean CSA of 
fibers in Mstn-/- mice did not increase as much as the wildtype (Mstn+/+) counterparts. 
Further on, differences in the individual fiber type classifications varied depending on 
the major MyHC expressed (Fig. 5). Significant increases in CSA were found in all fiber 
types; however, only fibers expressing MyHC lla and llx displayed a blunted growth 
response in the Mstn-/- group. Differences in size of fibers expressing MyHC lib were 
more modest and therefore no significant interaction was found. The comparison of the 
CSA of fibers expressing MyHC I could not be completed between the Mstn-/- and 
Mstn+/+ mice since no fibers were present in the Mstn-/- mice at 0 and 3 days. Two 
weeks after the surgery, only one mouse was found to have fibers expressing MyHC I. 
For the mean midbelly area (Fig. 4C), significant interactions were found (p<0.05). Mean 
midbelly area grew by 112% (p<0.05) in the wildtype (Mstn+/+), whereas the Mstn -/-
only grew by 23%. A drastic increase in midbelly area (46%; p<0.05) was observed in 
Mstn-/- mice 3 days following surgery most likely due to some inflammatory response in 
this group. To evaluate hyperplasia, the estimated cell count was obtained by dividing 
the mean midbelly area by its corresponding mean cross-sectional size of the individual 
fibers. The number of fibers increased significantly only after 6 weeks of overload in the 
' wildtype (Mstn+/+) mice. In Mstn-/-, a smaller non-significant increase was found. The 





Figure 5 Cross-sectional area of muscle fibers according to major MyHC expression 
Attenutation of fiber growth in Mstn-/- mice (closed bars) of fibers expressing A) MyHC I, B) MyHC lla, C) MyHC llx, D) 
MyHC lib compared to Mstn+/+ (open bars). Values for all graphs are means ± S.E. n=4-7 per treatment group. * 
different (p<0.05) from wildtype (Mstn+/+) counterpart, ¥ different (p<0.05) from non-overloaded control, H different 
from 3-day overloaded muscles, § different (p<0.05)from 2-week overloaded groups. 
MyHC expression in response to overload 
The statistical analysis of the overload-induced changes is presented in Table 2. In 
Mstn+/+ mice, a significant three-fold increase was found 2 weeks following surgery in 
the proportion of fibers expressing MyHC I (Fig. 6A). This proportion continued to 
increase over 7 times the initial level reaching 12%. Mstn-/- mice did not show the same 
response as there was a blunting in fiber type remodeling and only one mouse had 
MyHC I fibers 2 weeks post-surgery. After 6 weeks, less than 1% of all fibers were 
expressing MyHC I. At each t ime point in Mstn-/- mice, the proportion of fibers 
expressing MyHC lla fibers was significantly lower than Mstn+/+ mice (Fig. 6B). Both 
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groups showed a slight increase in the expression of MyHC Ha, however, the difference 
was not statistically significant. We observed only a tendency towards a greater 
proportion of fibers expressing MyHC llx in the Mstn-/- group (14%; p=0.051) (Fig. 6C). 
Mstn-/- mice had a larger proportion of fibers expressing MyHC lib and this difference 
was maintained throughout the time-course (Fig. 6D). Additionally, a substantial and 
significant loss in the proportions of MyHC Mb fibers (44%; p<0.05) was also observed in 
wildtype (Mstn+/+) animals only after 6 weeks. A different response was observed in 
Mstn -/- mice where the proportion was maintained, however, statistical analysis did 
not reveal any significant interactions. From these observations, the decrease in fibers 
expressing lib fibers in wildtype {Mstn+/+) mice corresponded to a concomitant increase 
in cells displaying MyHC I. Despite the initial high levels of expression of fast isoforms of 
MyHC in Mstn-/- muscles, these mice still maintained a capacity of the plantaris muscle 
to undergo the changes normally observed following functional overload. However, the 
response was blunted. 
Table 2 Statistical analysis results of MyHC expression 
p-values for the main effects and interactions of each variable. Asterisks denote significance (p<0.05) 
Variable KO effect OV effect Interaction 
Proportion of fibers 
expressing: 
MyHC I <0.001* <0.001* 0.002* 
MyHCIIa <0.001* 0.120 0.504 
MyHC llx 0.768 0.017* 0.153 
MyHC lib <0.001* 0.002* 0.335 
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Effects of overload on single fiber metabolic enzyme activity 
The amount of each enzyme per unit cross-sectional area (OD unit / min • urn2) 
of SDH and GPDH and total activities per cell (OD unit / min) were measured in control 
and 6 weeks overloaded mice (Fig. 7). There was a reduced amount of SDH activity per 
area (Fig. 7B) and total activity (Fig. 7C) in Mstn -/- mice compared to Mstn+/+ mice, 
however, only the amount of SDH activity per area was found to be significantly lower 
than its wildtype (Mstn+/+) counterpart. After 6 weeks of overload, the SDH rate per 
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Figure 6 Changes in expression of major MyHC isoforms 
Changes in the expression of myosin heavy chain isoforms display a blunting of transition from fast-to-slow as Mstn-/-
mice (closed bars) compared to their wildtype (Mstn+/+) counterpart (open bars). Values for all graphs are means ± 
S.E. n=4-7 per treatment group. * different (p<0.05) from wildtype (Mstn+/+) counterpart, ¥ different (p<0.05) from 
non-overloaded control, a different from 3-day overloaded muscles, § different (p<0.05)from 2-week overloaded 
groups. 
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Figure 7 Staining for metabolic enzymes SDH and GPDH (Preliminary) 
Reprensentative images of staining for A) SDH and D) GPDH. Quantification of staining of B) SDH activity per 
unit area of each cell, C) Total SDH activity per cell, E) GPDH activity of staining per unit area of each cell and 
F) Total GPDH actiivity per cell. Open bars: wildtype (Mstn+/+), closed bars: Mstn-/-. Values for all graphs are 
means + S.E. n=l per non-OV group; n=2-3animals per OV group. * different (p<0.05) from wildtype [Mstn+/+) 
counterpart, T different (p<0.05) from non-overloaded control. Scale bar: 100u.m 
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reflecting the larger cross-sectional area. The differences in the rates of activity in the 
Mstn+/+ mice were however not significant. On the other hand, in Mstn-/- mice, the 
rate of SDH activity per area and the total SDH activity was greater following 6 weeks of 
overload. With respect to GPDH rates in non-OV Mstn-/- muscle fibers, we observed 
60% (p<0.05) more activity per area and a doubling (p<0.05) of total activity when 
compared to its wildtype [Mstn+/+) counterpart. Following 6 weeks of overload, muscle 
fibers from Mstn+/+ animals showed an increase in GPDH activity per area and total 
activity with significant differences for the total activity. Fibers from Mstn-/- mice 
maintained their GPDH activity. 
Muscle damage and remodeling is more apparent in the distal portion of the plantaris 
Previous literature of ablation surgery performed on Mstn+/+ rodents shows 
very little or no inflammation at the midbelly. However, in our case, Mstn-/- mice 
display a very pronounced inflammatory response 3 days post-surgery marked by 
increased interstitial space, most likely due to edema and macrophage infiltration. 
When damage to muscle cells occurs, Evans blue dye (EBD) bound to albumin can enter 
those cells and the dye can be detected using a fluorescent microscope. Additionally, 
unspecific staining is detectable when staining only with a secondary Ig antibody. The 
unspecific staining found at the 3 day time point corresponded to labeling with EBD 
(data not shown). To further assess muscle damage after three days of overload, we 
obtained cross-sections of muscles stained with EBD at different levels in the belly of the 
muscle (Fig. 8A). As can be seen, only a very few cells are permeable to the dye in the 
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Mstn+/+ mice at the midbelly, whereas staining is visible in a good portion of cells in the 
whole midbelly of the Mstn-/- muscle. At each level, Mstn -/- mice consistently display a 
larger area of cells positive for EBD. The plantaris muscle is pennate and curiously, the 
uptake of EBD was mostly located in the belly region away from the tendon. 
Additionally, longitudinal sections were obtained which confirmed our findings (Fig. 8B); 
following overload, both groups displayed damage in the distal portion of the muscle, 
however, the insult was greater in Mstn-/- plantaris muscle. 
A) Mstn+/+ Mstn-/-
Figure 8 EBD uptake in 3-day overloaded muscles (Preliminary) 
Representative images of the uptake of EBD in muscle overloaded for 3 days. EBD uptake shows more damage in the 
Mstn-/- mice at A) midbelly, distal and +distal sections. +distal sections from non-overloaded mice were added as 
control to show absence of fluorescence in cells. n=2-3 per overload group; n=l per control group. B) Longitudinal 
sections reveal extent of damage in the whole muscle. n=2 for Mstn+/+ group; n=l for Mstn-/- group. White arrows 
show location of distal tendon on cross-sections and longitudinal sections. Scale bar in A) 200u.m and B) 500um. 
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Myogcnin BrdU DAPI Merge 
Figure 9 Immufluorescent images of 1-week overloaded muscles (Preliminary) 
Representative images of staining for myogenin (green), BrdU (red) and nuclei with DAPI (blue). Images from 
Mstn+/+ and Mstn-/- muscles reveal a greater colocalization in areas with more damage. n=2 per wildtype(M5tn+/+) 
group; n=l per Mstn-/- group. 
The distal portion of the plantaris was also a region of major remodeling. 
Immunofluorescence images from distal sections of plantaris muscles overloaded for 
one week are found in figure 9. In non-damaged areas of both groups, little or no BrdU 
was found indicating no regeneration in those regions. On the other hand, we observed 
a high concentration of nuclei colocalized with BrdU and myogenin in damaged areas. In 
the areas with larger interstitial space, many nuclei were found positive for BrdU, 
however, most were not expressing myogenin and were therefore not included in the 
analysis. Moreover, the one week time point corresponded to the appearance of cells 
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Figure 10 Embryonic cells after 1 week of overload 
A) Representative images of staining for embryonic MyHC isoform. Image of unspecific staining was used to identify 
cells cells expressing the embryonic MyHC. B and C) Quantification of embryonic cells. Values for both graphs are 
means ± S.E. n=4 per wildtype (Mstn+/+) group; n=2 per Mstn-/- group. Scale bar 200u.m. 
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expressing embryonic MyHC (Fig.lOA). The count of embryonic cells (Fig. 10B) was 
greater in the Mstn-/-, however, not significantly different. Additionally, no difference 
was found when normalizing the data to the distal belly area (Fig. IOC). 
To find more evidence of hyperplasia, we analyzed distal sections stained with 
hematoxylin and eosin. Cells wi th central nucleation were already present after one 
week of overload (Fig. 11). One week post-surgery, major remodelling, marked by small 
centrally nucleated cells and many nuclei located interstitially can be observed. The 
large intact cells found in the muscles of Mstn-/- plantaris muscles are mostly likely a 
result of remaining inflammation. After 2 weeks of overload, no more inflammation is 
seen. Both groups showed central nucleation, with some cells containing multiple 
nuclei. In fact, a few cells in Mstn-/- muscles contained up to 6 nuclei. Muscles from 
those displayed more cells with at least one central nucleus (Fig. 11B), more nuclei 
located centrally (Fig. 11D) and a greater proportion of all cells were centrally nucleated 
(Fig. 11C), however, only the total number of centrally located nuclei showed a 
tendency for significance. To find out whether the muscles had returned to their pre-
overloaded state, we stained and analyzed the muscles of mice overloaded for 6 weeks. 
To our surprise, centrally nucleated cells were still present (Fig. 11A & E-G).Mstn-/- mice 
showed significantly more cells with at least on central nucleus, more nuclei located 
centrally, and a greater proportion of centrally nucleated cells than their wildtype 
counterparts. 
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Figure 11 Central nucleation 
A) Representative images of H&E in non-OV, 1- 2- and 6-week overloaded muscles. Scale bar 50 u.m 
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Figure 11 (cont'd) 
Central nucleation after B-E) 2weeks and E-G) 6 weeks of overload. Values are means ± S.E. n=2-5 animals per 
treatment group. * different from wildtype (Mstn+/+) group. 
Western blots show activation of satellite cells 
Protein levels of pax7, myoD and myogenin reflect activation of satellite cells (Fig. 12). 
Under control conditions, pax7 protein levels are similar in wildtype (Mstn+/+) and 
Mstn-/- mice. Following the surgery, we observed an increase in pax7 protein levels in 
both groups (3.5 fold in both groups). In non-overloaded mice, a greater non-significant 
myoD level was observed (44%; p>0.05) in Mstn-/- mice. Following overload, myoD 
levels rise significantly after 1 day in Mstn+/+ mice (3.4 fold increase; p<0.05). After 3 
days, myoD in wildtype (Mstn+/+) remained slightly elevated (2.3 fold), however, not 
significantly different from its non-overloaded control. In Mstn-/- mice, myoD protein 
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Figure 12 Pax7, myoD and myogenin relative protein levels 
Quantification of A) pax7 B) myoD and C) myogenin protein levels in Mstn+/+ (open bars) and Mstn-/- (closed bars). 
Values are relative to the Mstn+/+ non-overloaded control. Values are means ± S.E. n=2-3 per treatment group. * 
different from respective Mstn+/+ (p<0.05). ¥ Different from non-overloaded control (p<0.05). § Different from 1 day 
overloaded (p<0.05). H Different from 3 day overloaded (p<0.05). 
As for myogenin, a different pattern of expression was observed, however, no significant 
interactions were found. In the control group, no significant difference was found in the protein 
level (23% higher, p>0.05). After 1 day, myogenin levels were significantly higher in Mstn+/+ 
mice (4.1 fold; p<0.05) and remained elevated up to 3 days following overload (4.4 fold; p<0.05). 
Interestingly, myogenin protein levels increase after 1 day (4.2 fold; p<0.05), but return to their 
non-overloaded level after 3 days. These data show that satellite cells are activated and have 
committed to the myogenic lineage. 
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Discussion 
We used the functional overload model to examine differences in the growth 
response between Mstn-/- and Mstn+/+ mice. Contrary to our hypothesis, the growth in 
Mstn-/- mice was not potentiated but in fact blunted. With the exception of absolute 
muscle mass and cross-sectional size of Mb fibers, all variables measuring size show a 
significant or a tendency (P<0.06) towards a significant interaction where the muscles of 
Mstn-/- mice did not grow to the same extent as their wildtype [Mstn-/-) counterparts. 
Following 2 and 6 week of overload, the cross-sectional area of muscle fibers of all 
individual fiber types from Mstn+/+ mice exceeded that of Mstn-/- mice. On the other 
hand, the overall cross-sectional area of fibers irrespective of their MyHC type was still 
greater in Mstn-/- compared to wildtype (Mstn+/+) counterparts. This could be 
explained by the greater proportion of the larger MHC Mb fibers in Mstn-/-. The 
proportion of those larger fibers was also maintained after 2 and 6 weeks in Mstn-/-. In 
non-overloaded animals, the absence of myostatin leads to significant muscle size, 
however, the improved strength is not proportional to the greater muscle mass [154]. 
This could partially explain the lack of growth seen in our Mstn-/- mice following 
overload suggesting the plantaris muscle was not stressed enough to induce growth. 
Recent evidence suggests endurance exercise alone does not induce hypertrophy, but 
rather a switch towards a more oxidative phenotype[102, 103]. In those studies, muscle 
fiber size was maintained or slightly reduced following endurance exercise suggesting 
hypertrophy is a result of the increased load on the plantaris muscles rather than a 
response to exercise. Another possible explanation could be that these mice might have 
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potentially reached their maximal size. This is highly unlikely, since targeting other 
ligands in addition to myostatin quadruples muscle mass in mice[155]. Our results then 
suggest that other pathways are able to compensate for the lack of myostatin, namely 
activin orfol l istatin. 
We replicated previous results showing a greater proportion of fibers expressing MyHC 
llb[137, 156]. We also displayed a blunted capacity for Mstn-/- to adapt to increased 
load which concords with previous findings[102,103]. The absence of fibers expressing 
MyHC lib could stem from a reduced fatigue-resistance to exercise[102], however, our 
data (not shown) supports similar levels of daily volunteer running. This would suggest 
myostatin would be important in the expression of slow MyHC isoforms. Interestingly, 
myostatin is found more abundantly in fast muscles[157]. Calcineurin is an important 
regulator of the fast to slow fiber conversions that occur during overload[135]. 
Myostatin could act in cooperation with calcineurin in fiber type remodeling[158, 159]. 
In agreement with previous reports, we found lower SDH activity in Mstn-/- mice which 
also matches the absence of the fibers expressing the MyHC I isoform[160]. To further 
characterize the capacity of skeletal muscles in Mstn-/- mice to adapt to the functional 
demands of overload, we assessed SDH and GPDH activity. Endurance exercise induced 
an increase in SDH activity in both Mstn-/- and wildtype (Mstn+/+) mice. Strangely, 
functional overload led to a greater increase of SDH activity in Mstn-/- mice. The 
increase in oxidative capacity did not concord with the blunted response in the different 
MyHC isoforms. Moreover, the final SDH activities were similar in both groups. This 
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would suggest a great capacity of muscle fibers to adapt to increased demands 
irrespective of the contractile properties of their MyHC isoforms. On the other hand, as 
expected, GPDH activity was significantly higher in Mstn-/- control mice. Additionally, 
the increase in GPDH activity in Mstn+/+ mice matched previous findings from our 
laboratory[136]. Overloaded Mstn-/- muscles maintained their GPDH activity and final 
levels were similar to the wildtype (Mstn+/+) group. Possibly, muscles from Mstn-/-
mice could retain their levels of GPDH activity since they do not follow the traditional 
fiber remodeling towards slower, more energy efficient phenotypes. GPDH activity 
would reflect the load requirements and not the muscle recruitment frequency. 
The uptake of EBD clearly shows more damage in overloaded Mstn-/- muscles. To 
explain the greater damage found in Mstn-/- mice, myostatin increases the expression 
of collagen genes and promotes collagen formation[161, 162]. Myostatin-deficient mice 
also have smaller and brittle tendons making the tendons more susceptible to 
damage[163]. This aspect becomes particularly important for the populations that might 
benefit from treatment through the inhibition of the myostatin pathway. Elderly people 
have altered tendon mechanical properties[164], and if myostatin is required for 
collagen expression, such a therapy could be devastating. With training, tendon 
mechanical properties such as cross-sectional area, length and stiffness can be 
improved[165, 166]. Since disuse can lead to the opposite effect[166], it would be 
interesting to see whether the reduced collagen expression is a result of the genetic 
mutation or a consequence of abnormally large muscles not used to their full extent. 
Another explanation for the greater damage includes a greater angle of pennation 
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leading to differences in the biomechanical force transmission through the muscle fiber. 
Interestingly, myostatin is located at the myotendinous junctions possibly providing 
protective effects[167]. Body weight could also play a factor, however, Mstn+/+ mice 
with similar body weights to Mstn-/- mice were overloaded and the Mstn-/- mice still 
displayed more muscle damage (data not shown). Whether damage is necessary for 
remodeling is still uncertain. Intuitively, more damaged areas would trigger more 
regeneration and our findings support this idea. 
Inflammation is an important process in early regeneration which facilitates myogenesis 
via phagocytosis of cellular debris and the release of growth factors[141, 168-170]. 
Ibuprofen, a non-steroidal anti-inflammatory and analgesic drug, is a selective inhibitor 
of the cyclooxygenase (COX) pathway[171] involved in skeletal muscle 
regeneration[172]. The treatment with COX inhibitors does not affect the weight of non-
injured muscles[172], and therefore, our control non-overloaded animals were not 
given any ibuprofen. Since it is not involved in muscle damage, it would not affect the 
absorption of EBD in overloaded muscles. Additionally, daily treatment with COX 
inhibitors can block skeletal muscle hypertrophy induced by functional overload[173]. In 
our study, ibuprofen was removed after 3 days when no differences in macrophage 
accumulation have been previously observed[173]. 
Since the plantaris muscle of Mstn-/- mice did not grow as much as those of their 
wildtype counterparts {Mstn+/+) after 2 and 6 weeks of overload, we looked at earlier 
t ime points to determine satellite cell activation. Previous studies have shown an 
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upregulation in myogenic markers after just 1 day and started to decline only after 7 
days[174]. Distally, more nuclei were labeled with BrdU and more labeled nuclei 
colocalized with myogenin. Our findings concur with previous findings observing 
myogenin localized in the nuclei after 7 days of overload[175,176]. The same group also 
found myoD and myogenin to be expressed before PCNA, an indicator of proliferation, 
could be observed. The early expression of those MRFs suggests that a first of wave 
myogenic precursor cells can differentiate into myotubes without proliferating. If more 
extensive damage occurs, the remaining satellite cells can divide to provide the 
necessary cells to complete the regeneration. The regions surrounding the damage were 
filled with cells staining for the embryonic isoform of myosin indicating new cell 
formation. Despite the greater number of cells expressing embryonic MyHC, the value 
normalized to the belly area revealed no difference from control. More damaged areas 
were found in the overloaded muscles of Mstn-/- mice and therefore secondary binding 
could potentially hide some embryonic cells. Additionally, one of our wildtype mice 
(Mstn+/+) showed more embryonic cells than its Mstn-/- counterpart, suggesting a great 
amount of variability in the response. Moreover, larger areas of fiber regeneration were 
found in the muscles overloaded for 1 week in Mstn-/- animals. 
An analogy to muscle regeneration can be made with the mdx mouse. The mdx mouse, 
a genetic ortholog of Duchenne and Becker muscular dystrophies, provides a model 
system for repetitive muscle degeneration and regeneration. In the mdx mouse, a 
mutation in the gene for dystrophin results in absence of the protein from the 
sarcolemma and muscle fiber necrosis[177]. Satellite cells are involved in the 
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regeneration of muscles affected by muscular dystrophy; however, the progressive 
degeneration leads to a decrease in satellite cell number and proliferative 
potential[178]. Beneficial effects from myostatin absence or blockade have been 
reported possibly due to increased proliferation of satellite cells[10,179]. 
The requirement for satellite cell activity in muscle hypertrophy is still debated[57, 60, 
176, 180]. Most studies opposing the addition of new cells looked at the role of the Akt 
pathway in muscle growth. On the other hand, studies using the functional overload 
model support the idea of hyperplasia. The most convincing evidence supporting 
hyperplasia comes from studies using irradiation to suppress the mitotic capability of 
satellite cells. Since mature skeletal muscle fibers are post-mitotic, lack of growth 
following overload clearly demonstrates the importance of satellite cells in hypertrophy 
[58,180, 181]. To further support the requirement of satellite cells for hypertrophy, 
inhibition of satellite cell activation has also blocked overload-induced growth[182]. 
Following overload, muscle mass can double within 2-4 weeks, however, in our lab, 
proliferation of satellite cells has not been found to a be major contributor to the rapid 
growth[91]. Most recently, a contradicting study involving myostatin signaling refuted 
hyperplasia as a major contributor to the larger muscle mass observed in Mstn-/-
mice[51]. The authors of the study used lower concentrations of myostatin to inhibit 
satellite cell proliferation. Additionally, they used aged mdx animals to demonstrate that 
myostatin absence does not rescue the dystrophic phenotype. Therefore, we still 
believe that myostatin is still involved in satellite cell activation and proliferation. Our 
findings of satellite cell activity might explain why little evidence has been found of 
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newly formed cells in the midbelly region of overloaded muscles. In vitro, lack of 
myostatin in the differentiation medium delays the differentiation process and would 
therefore allow to prolong the proliferation of myoblasts[49]. Closer to the 
myotendinous junction, after one week, the appearance of cells expressing the 
embryonic isoform of MyHC, followed by central nucleation after 2 weeks of overload 
provide some evidence of hyperplasia. Supporting this idea, in Mstn-/- mice, we 
observed a greater number of centrally nucleated cells per mm2 and a greater number 
of nuclei located centrally at the distal ends of the plantaris muscle after 2 and 6 weeks 
of overload. Despite the lack of significance between the groups at 2 weeks, combining 
results at the midbelly and distal sections would most likely show a greater propensity 
for Mstn-/- muscles to grow through hyperplasia. Moreover, no differences in the 
estimated cell count were observed at the midbelly area after 6 weeks suggesting an 
important role for growth in the distal portion of the muscle. Our data obtained at the 
midbelly of muscle mass, cross sectional area and proportions match previous findings. 
Thus changes observed at the midbelly do not reflect the remodelling in the distal 
portion of the muscle. In light of the regeneration occurring in the distal portion of the 
plantiaris muscle, further characterization is necessary to assess the changes associated 
with functional overload. 
The IGF/Akt pathway might also be involved in the hypertrophic response resulting from 
functional overload. However, some studies suggest a limited role. By inhibiting IGF, 
hypertrophy was not blocked following synergist ablation[55]. Although IGF and Akt can 
induce hypertrophy in vivo, they have a limited role in satellite cell activation[60, 183]. 
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To further support this, irradiated muscles still grow when treated with IGF-I although to 
a lesser extent[57]. This suggests the IGF-I pathway induces hypertrophy through 
increased protein synthesis. 
Moreover, our preliminary western blots did not show any differences between 
Mstn+/+ and Mstn-/- mice. Our results showed a peak in the regulatory proteins after 1 
day of overload, and returning to basal levels after 3 days, earlier than previously 
found[87]. Differences among species could explain the differences in the response. 
Myogenin levels were maintained up to 3 days in wildtype mice; however, the 
difference was not significant. If proliferation only begins after 3 days marked by an 
upregulation of PCNA[174], a second peak could be seen at later time points explaining 
the presence of myogenin in the nuclei found with our immunofluorescence. 
Our study not only shows hyperplasia as a major contributor to growth in Mstn-/- mice, 
but it also calls us to revisit the current notion about muscle growth in general. 
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Abstract 
Myostatin is a member of the TGF-R family of growth factors and a negative regulator of 
muscle mass. Myostatin has been proposed a therapeutic agent to prevent atrophy. To 
investigate the role for Mstn in muscle fiber atrophy, we compared the effects of 
denervation in Mstn Knockout (Mstn -/-) and wildtype (Mstn+/+) mice. Two weeks of 
denervation led to significant and comparable loss in muscle mass of the soleus and 
plantaris of the wildtype (Mstn+/+) and Mstn-/- mice. The comparably lower mass was 
concomitant with reduction of the cross-sectional area of individual fibers in the 
plantaris and soleus muscle in both sets of mice. During the same time frame, no 
significant changes in myosin heavy chain type profiles of Mstn+/+ and Mstn-/- muscles 
were found. This study shows no sparing effect of the absence of myostatin during 
skeletal muscle atrophy following denervation suggesting an alternative pathway for 
nerve-mediated atrophy. Funded by CIHR, NSERC and CRC. 
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Introduction 
Muscle atrophy in animal models is regulated in response to changes in workload, 
activity and in the presence of pathological conditions [66,184]. Muscle degeneration 
may lead to a debilitating condition which is often seen in disuse, aging, and muscular 
dystrophy. Despite the importance and impact of losing muscle mass, the mechanisms 
leading to atrophy are still poorly understood. The same biochemical and chemical 
changes are believed to occur in muscles during the various types of atrophy [185]. 
Myostatin, an important regulator of skeletal muscle mass, is increased in many 
different models of atrophy[78-81]. Myostatin is expressed in skeletal muscle and in 
heart[2,186]. Once synthesized, myostatin is processed and secreted into the blood 
stream[2, 16]. 
Myostatin inhibition, for instance via the administration of antibodies against this 
protein, has been proposed as a method to limit muscle atrophy after paralysis since the 
disruption of its gene expression leads to dramatic increases of skeletal muscle mass[2]. 
Loss of myostatin results in a combined effect of muscle fiber hypertrophy and 
hyperplasia[2]. Myostatin loss in dystrophic mice through its inhibition by injection or 
gene deletion results in increased muscle mass and muscle strength[12]. Also, removal 
of myostatin improves the sarcopenic phenotype [13]. To date, the only studies looking 
at the rescuing effects of skeletal muscle atrophy have used glucocorticoid 
administration or hindlimb unloading to induce muscle atrophy[187,188]. 
Denervation requires the removal of a portion of a nerve which leads to complete loss 
of neural input and muscle activity. Atrophy varies greatly due to the function of the 
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different muscles (weight bearing versus non-weight bearing; fast versus slow). Changes 
in the expression of the different isoforms of MyHCs are also observed following 
denervation[106,114]. The direction of the change depends on the predominant fiber 
type of the muscle prior to denervation[106,115]. Fast muscles develop a tendency 
towards a slower phenotype and slow muscle show a shift towards a faster phenotype. 
Additionally, many genes are differentially expressed during denervation. MuRFl and 
MAFbx are among the mRNA most drastically induced by denervation[66, 109,110]. The 
expression of those genes is dependent on the FoxO family of transcription factors, 
FoxOl and Fox03a[74, 109, 111]. 
Myostatin knockout has led to amelioration in muscle phenotype after injection of 
glucocorticoids[187]. However, the myostatin knockout muscles were not spared fom 
atrophy when subjected to gravitational unloading[188]. Therefore, in our study, we set 
to assess the effects of denervation-induced atrophy on weight bearing muscles when 
myostatin is not present. 
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Materials and methods 
Animal care and protocols 
All animal care and experimental procedures were performed in accordance with 
the guidelines established by the Canadian Councilof Animal Care. These procedures 
were approved by the University Animal Research Ethics Committee (UAREC) of 
Concordia University. Mstn-/- mice were kindly donated by Dr. S.-J. Lee. (Johns Hopkins 
University School of Medicine, Baltimore, MD) 
Animal surgeries 
All surgical procedures were performed under aseptic conditions on animals 
anesthetized by intramuscular injection (1.2 pl/g) of 100 mg/ml ketamine hydrochloride 
and 10 mg/ml xylazine in a volume ratio of 1.6:1. Under sterile conditions, the sciatic 
nerve was exposed at the level of the sciatic notch. A segment of 4-5 mm of the sciatic 
nerve was excised just below the sciatic notch. The contralateral limb was left 
untouched. Additionally, non-operated mice were used as control. The mice were kept 
denervated for 3, 7 or 14 days. To ensure full denervation, neurological tests were 
performed as described previously[189]. Following the treatment period, the animals 
were deeply anesthesized again and the soleus, plantaris, gastrocnemius, plantaris and 
tibialis anterior were excised, embedded in OCT (Tissue-Tek, Torrance, CA) and frozen in 




Antibodies used were as follows: MyHC I: A4.840, Developmental study hybridoma 
bank (DSHB, University of Iowa, Iowa city, IA); MyHC lla : SC71 (DSHB); MyHC llx : 6H1 (DSHB); 
MyHC Mb : BF-F3 (DSHB); anti-mouse HRP : IgG A8924 (Sigma-Aldrich) or IgM A8786 (Sigma-
Aldrich). To determine the MyHC isoform expressed by each fiber, cryosections (10 u.m) 
were cut from the same anatomical location in each muscle midbelly and recovered 
onto Superfrost Plus microscope slides (Fisher Scientific). First, the sections were 
blocked in 5% goat serum in a carrier solution consisting of 0.5% bovine serum albumin 
(BSA) in 25 mM PBS (pH = 7.4) for 30 minutes. The sections were then probed overnight 
at 4°C in carrier solution with one of the following primary antibodies raised against the 
different MyHC types (I 1:25; lla 1:12.5; llx undiluted; Mb 1:25). After three 10-min PBS 
rinses, sections were then probed at room temperature with either horseradish 
peroxidase-conjugated anti-mouse IgG (MyHC type lla 1:25) or IgM (MyHC type I, llx, lib. 
The sections were rinsed three times with PBS for 10 minutes. The bound antibody 
complexes were then visualized using DAB as per the manufacturer's instructions. DAB 
makes the bound peroxidase-conjugated antibodies turn brown and can be visualized 
with a light microscope. 
Three to four distinct regions were selected randomly from the midbelly of each 
plantaris and soleus muscle. All fibers in those regions were identified across each serial 
tissue section with the aid of a Retiga SRV camera (Qlmaging, Surrey, BC, Canada) 
mounted on an Olympus BX-60 (Olympus, Center Valley, PA) microscope. Each area of 
interest comprised approximately 75 fibers. The images were analyzed using ImagePro 
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Plus version 6.2 software (Olympus). Fibers were classified according to their staining 
profile with the distinct antibodies. For consistency, cell size was measured on a single 
non-stained muscle section fixed with 1% paraformaldehyde for 20 minutes in PBS 
followed by 3 washes in PBS for 5 minutes each. 
Protein extraction and immunoblotting 
The antibodies used were: Myostatin : AB3239,1:750 (Millipore, Bedford, MA); alpha 
tubulin : 2125,1:2000 (Cell Signaling Technology); anti-rabbit HRP : 7074,1:2000 (Cell Signaling 
Technology). Muscles were homogenized in RIPA buffer [PBS (pH 7.4), 1% Igepal, 0,5% 
Sodium deoxycholate, 0,1% SDS, 10 u.g/ml leupeptin, 10 u.g/ml aprotinin, 1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride, 10 mM NaF, and 1 mM sodi um ortho vanadate] 
using a TissueTearor homogenizer (ColeParmer, Montreal, OX) at low speed for 45 
seconds. Homogenateswere centrifuged at 13 000 x g for 30 min at 4 C to pellet cell 
debris. The supernatant was quantified using the QuickStart Bradford dye reagent (Bio-
Rad, Mississauga, Ontario, Canada). For protein analysis, 150 ug protein were resolved 
by SDS-PAG, transferred to a PVDF membrane (Millipore). The protein/antibody complex 
was revealed by chemiluminescence using the Immobilon Western kit (Millipore). 
Statistical analytsis 
The data was tested for homogeneity of variance, and in the case where homogeneity 
was found, a two-way ANOVA was used. LSD was used as a post hoc test when 
appropriate. When the variance between the groups was not homogenous, the Kruskal-
Wallis test was performed. The statistics were done with computer assistance using 
SPSS Statistics GradPack version 17.0. 
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Results 
Myostatin protein is found in muscles and serum 
To confirm the presence of of myostatin protein, we immunoblotted 150|ig of protein 
from skeletal muscle, heart and blood serum of wildtype (Mstn+/+) mice (Fig. 13). We 
used the Mstn-/- mouse as a control for the antibody. The data show that myostatin 
protein is easily detected as the precursor form in skeletal muscle of wildtype (Mstn+/+) 
mice. A very faint band at 13kDa can be seen in the skeletal muscle of Mstn+/+ mice. 
Since active myostatin is secreted into the blood stream, only the active portion (13kDa) 
is visible in plasma of Mstn+/+ mice. Myostatin was, however, not detectable in the 
heart. The absence of bands at the corresponding height of 13 and 55kDa in the lanes 
containing Mstn-/- samples confirms the specificity of the myostatin antibody. 
Figure 13 Myostatin protein in skeletal muscle, heart and blood serum (Preliminary) 
Western blot for myostatin protein in skeletal muscle (lanes 1&2), heart (lanes 3&4) and blood serum (lanes 5-8). 
Myostatin'is present in Mstn+/+ mice (lanes 1,3,5,6) and absent in Mstn-/- mice (lanes 2,4,7,8). Myostatin is detected 
as the precursor protein in skeletal muscle and as the active protein in blood serum. Myostatin was not found at 
detectable levels in the heart. Quantity loaded: 150p.g in each lane. n=l for skeletal muscle and heart; n=2 for serum 
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Muscle mass loss is not different in Mstn-/- mice 
Absolute muscle mass is displayed in Figure 14 (A-C). Additionally, to control for the 
difference in body weight, we divided the absolute muscle weight by the animal's body 
weight to obtain the relative muscle mass (Fig. 14D-F). A significant denervation effect 
was observed in all weight bearing muscles of both wildtype {Mstn+/+) and Mstn-/-
mice. In Mstn+/+ mice, denervation induced a significant reduction in absolute and 
relative muscle mass of 25 to 40% in the soleus, plantaris and gastrocnemius muscles. 
Similar results were observed in the Mstn-/- muscles. These data show no sparing effect 
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Figure 14 Muscle weights 
Absolute (A-C) and relative (D-F) muscle mass of soleus (A,D),plantaris (B,E) and gastrocnemius (C,F). Open bars: Non-
denervated controls; black bars: Contralateral limb to denervated side; gray bars: Denervated limb. Values are means 
+ S.E. n=3-4 per treatment group. * Different from wildtype (Mstn+/+) (p<0.05); ¥ Different from non-denervated 
control (p<0.05); § Different from contralateral limb (p<0.05). 
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Changes in CSA are similar in Mstn+/+ and Mstn-/- mice 
We used fiber CSA as another measure of atrophy (Fig. 15). In plantaris, fibers 
expressing the different MyHC isoforms displayed different sensitivities with respect to 
size in response to denervation (Fig. 15A). More specifically, only fibers expressing 
MyHC Mb showed atrophy compared to fibers in the contralateral limb and the non-
denervated muscles. The size difference was similar in wildtype (Mstn+/+) and Mstn-/-
mice. No difference in size was apparent in fibers expressing other MyHC isoforms. 
In contrast to the plantaris, with the exception of MyHC lib fibers, all myofibers displayed a 
smaller CSA following denervation (Fig. 15B). The changes in CSA in both wildtype (Mstn+/+) and 
Mstn-/- mice correspond to the muscle mass lost in the soleus. 
Expression of MyHC isoforms 
We assessed changes in the expression of the major isoforms of MyHC in plantaris and 
soleus muscle fibers after 14 days of denervation (Fig. 16). In order to eliminate 
discrepancies due to the coexpression of different isoforms of MyHC in a single fiber, 
the proportion of the fibers were pooled into their major isoforms. Detectable changes 
in plantaris major MyHC profiles were not apparent after 14 days of denervation in both 
groups (Fig. 16A). In contrast to the plantaris, subtle transitions in Mstn+/+ mice in adult 
MyHC expression were observed within this same time frame under certain conditions 
in the soleus, such that the lla MyHC isoform was expressed in a greater proportion of 
cells, whereas some cells were no longer expressing MyHC I (Fig. 16B). In Mstn-/- mice, 
changes in MyHC expression were prevented in the denervated limb. 
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Figure 15 CSA of muscle fibers following 2 weeks of denervation 
Fiber CSA in A) plantaris and B) soleus muscles. Values are means ± S.E. n=3-4 per treatment group. H different from 
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Figure 16 Expression of major MyHC isoforms after 2 weeks of denervation 
Major MyHC expression in A) plantaris and B) soleus muscles. Values are means ±S.E. n=3-4 per treatment group. 
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Discussion 
In the present study, we compared the atrophic response of plantaris and soleus muscle 
fibers in wildtype (Mstn+/+) and Mstn-/- mice. Treatments inhibiting the myostatin 
pathway have previously been successfully used in muscular dystrophy and 
sarcopenia[12,13]. Myostatin also interacts with Akt and FoxO to modulate 
hypertrophy and atrophy. Therefore, we speculated that Mstn-/- mice would not lose as 
much muscle mass as Mstn+/+ mice. 
To date, the only studies looking at the rescuing effects of skeletal muscle atrophy have 
used the glucocorticoid or unloading model[187,188]. When treated with 
glucocorticoids, the removal of myostatin was effective at preserving muscle mass 
[187]. Opposing this study, disuse atrophy was not prevented by myostatin deficiency 
[188]. In fact, more muscle mass was lost in mice lacking myostatin. Interestingly, 
hindlimb suspension did not cause any atrophy in the soleus muscle of Mstn+/+ 
mice[188]. We report that the absence of myostatin does not prevent atrophy induced 
by denervation. This was supported by the similar response in wildtype [Mstn+/+) and 
Mstn -/- mice of muscle mass loss and decrease in CSA of individual fibers. 
Additionally, the proportions of the different isoforms of MyHCs did not change 
significantly after the experimental period in both plantaris and soleus muscles. Our 
findings match a recent study where changes in MyHC I were not observed following 1 
month of denervation in mice[105]. The half-life of MyHCs is approximately two 
weeks[190] and, therefore, changes in the MyHC expression might not have been 
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detectable within our experimental design. The soleus muscle did, however, show a 
trend towards a faster phenotype. 
The absence of myostatin in the soleus muscle could explain our results[81]. The plantaris 
does have myostatin, however, atrophy in Mstn-/- mice was not spared either. Furthermore, 
myostatin mRNA was found to be upregulated after 1 day of hindlimb suspension but 
returned to basal levels on the 3r day despite progressive atrophy of hindlimb 
muscles[81]. 
The secretion of myostatin into the bloodstream suggests that myostatin could 
potentially have a systemic role in signaling. Serum levels of myostatin have been 
assessed in heart dysfunction[191,192]. The Western presented in this manuscript To 
date, no study has looked at serum levels of myostatin induced by atrophy in skeletal 
muscle. Therefore, it would be very important to assess changes of myostatin levels in 
both skeletal muscles and serum. Additionally, activin Mb receptor have been located on 
different organs including brain, adipose tissue, ovaries and testis[193,194]. Whether 
myostatin signals through these receptors is still unknown, however, future studies 
could reveal novel roles of myostatin. 
In light of these results, we suspect another signaling pathway might take precedence 
over the myostatin pathway, possibly the activin or 1GF-I/Akt pathway. 
To properly understand the mechanisms by which myostatin mediates atrophy, further 
experiments are needed. First, whether similar levels of atrogenes are induced by 
denervation, immunoblots against MuRFland MAFbx should be determined. The 
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induction of MAFbx and MuRFl are mediated by FoxO proteins and therefore, 
antibodies for the FoxOs and their phosphorylated forms may provide evidence for their 
involvement. 
Just as myostatin, activin is known to bind to activin receptor lib and activate the same 
signaling cascade through Smad2 and Smad3[18]. Activin is involved in muscle growth 
and can partially replace myostatin's function in its absence[187]. Thus, whether activin 
or another ligand is activating the atrophy pathway through the Smad proteins needs to 
be determined. 
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Chapter 4: Conclusion 
In this thesis, I presented two preliminary manuscripts to elucidate myostatin's role on 
determining fiber size under conditions that either induce adult muscle growth or 
atrophy. In the absence of myostatin, muscle mass is greater. Knowledge about the 
regulatory processes involving myostatin is progressing, however, due to other 
pathways' involvement during growth a full understanding of these processes is lacking. 
In response to functional overload, we were expecting more muscle growth to occur in 
Mstn-/- mice, but surprisingly, we found that the absence of myostatin leads to a 
different strategy being employed to achieve growth. We observed a blunted muscle 
growth in Mstn-/- mice compared to wildtype counterparts. Mstn-/- mice displayed 
more muscle damage in response to functional overload which resulted in a greater 
hyperplasia response through satellite cell activation and proliferation. 
On the other hand, we thought myostatin might save muscles from denervation-
induced atrophy, but unfortunately muscles from Mstn-/- mice were not spared with 
similar losses of muscle mass and cross-sectional area in both wildtype and Mstn-/-
mice. This suggests other regulatory processes are in place to compensate for the lack of 
myostatin. Further experiments are required to discover which pathway took 
precedence over myostatin. These findings have implications in nerve-mediated atrophy 
and paralysis in humans where myostatin treatment might not be beneficial. 
Further on, recent findings about myostatin therapy have raised interest in sports. 
Besides the doping issue, the potential muscle growth could improve sports 
performances. Unfortunately, the highly regenerative potential of satellite cells could 
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eventually be depleted after increased proliferation due to myostatin removal[13]. 
Although aged mice lacking myostatin display a greater number of satellite cells and 
their regenerative capacity is better than their age-matched wild type coun te rpa r t s^ ] , 
little is known about long term effect on satellite cell population in humans. 
In conclusion, this thesis shows that myostatin is not the only regulator of adult skeletal 
muscle mass in both growth and atrophy. Other pathways or regulatory protein must 
function in synergy or in parallel with myostatin to control muscle mass. This type of 
redundancy is very common in biology and serves to compensate for the absence or 
malfunction of a specific gene[195]. 
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Appendix B: Summary of values used for denervation: 
Soleus muscle 
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